126 related articles for article (PubMed ID: 33026041)
1. Supramolecular hybrids of carbon dots and dihydroartemisinin for enhanced anticancer activity and mechanism analysis.
Li Y; Shi N; Zhang W; Zhang H; Song Y; Zhu W; Feng X
J Mater Chem B; 2020 Nov; 8(42):9777-9784. PubMed ID: 33026041
[TBL] [Abstract][Full Text] [Related]
2. MOF nanoparticles with encapsulated dihydroartemisinin as a controlled drug delivery system for enhanced cancer therapy and mechanism analysis.
Li Y; Song Y; Zhang W; Xu J; Hou J; Feng X; Zhu W
J Mater Chem B; 2020 Aug; 8(33):7382-7389. PubMed ID: 32648887
[TBL] [Abstract][Full Text] [Related]
3. A redox-responsive dihydroartemisinin dimeric nanoprodrug for enhanced antitumor activity.
Li Y; Pei Q; Cui B; Zhang H; Han L; Li W; Zhu W; Feng X; Xie Z
J Nanobiotechnology; 2021 Dec; 19(1):441. PubMed ID: 34930288
[TBL] [Abstract][Full Text] [Related]
4. Acidic Environment-Responsive Metal Organic Framework-Mediated Dihydroartemisinin Delivery for Triggering Production of Reactive Oxygen Species in Drug-Resistant Lung Cancer.
Yan X; Zhao X; Fan M; Zheng W; Zhu G; Li B; Wang L
Int J Nanomedicine; 2024; 19():3847-3859. PubMed ID: 38708182
[TBL] [Abstract][Full Text] [Related]
5. Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol-dihydroartemisinin conjugate.
Liu K; Dai L; Li C; Liu J; Wang L; Lei J
Sci Rep; 2016 Jul; 6():29461. PubMed ID: 27377918
[TBL] [Abstract][Full Text] [Related]
6. Self-assembly and self-delivery of the pure nanodrug dihydroartemisinin for tumor therapy and mechanism analysis.
Li Y; Zhang W; Shi N; Li W; Bi J; Feng X; Shi N; Zhu W; Xie Z
Biomater Sci; 2023 Mar; 11(7):2478-2485. PubMed ID: 36763165
[TBL] [Abstract][Full Text] [Related]
7. Novel multiarm polyethylene glycol-dihydroartemisinin conjugates enhancing therapeutic efficacy in non-small-cell lung cancer.
Dai L; Wang L; Deng L; Liu J; Lei J; Li D; He J
Sci Rep; 2014 Jul; 4():5871. PubMed ID: 25070490
[TBL] [Abstract][Full Text] [Related]
8. Preparation of Responsive Carbon Dots for Anticancer Drug Delivery.
Feng T; Zhao Y
Methods Mol Biol; 2019; 2000():227-234. PubMed ID: 31148018
[TBL] [Abstract][Full Text] [Related]
9. Enhanced apoptotic effects of dihydroartemisinin-aggregated gelatin and hyaluronan nanoparticles on human lung cancer cells.
Sun Q; Teong B; Chen IF; Chang SJ; Gao J; Kuo SM
J Biomed Mater Res B Appl Biomater; 2014 Apr; 102(3):455-62. PubMed ID: 24039154
[TBL] [Abstract][Full Text] [Related]
10. Dihydroartemisinin Sensitizes Mutant p53 (R248Q)-Expressing Hepatocellular Carcinoma Cells to Doxorubicin by Inhibiting P-gp Expression.
Yang Y; He J; Chen J; Lin L; Liu Y; Zhou C; Su Y; Wei H
Biomed Res Int; 2019; 2019():8207056. PubMed ID: 31976328
[TBL] [Abstract][Full Text] [Related]
11. PEGylated-Paclitaxel and Dihydroartemisinin Nanoparticles for Simultaneously Delivering Paclitaxel and Dihydroartemisinin to Colorectal Cancer.
Phung CD; Le TG; Nguyen VH; Vu TT; Nguyen HQ; Kim JO; Yong CS; Nguyen CN
Pharm Res; 2020 Jun; 37(7):129. PubMed ID: 32548664
[TBL] [Abstract][Full Text] [Related]
12. Effects of magnetic dihydroartemisinin nano-liposome in inhibiting the proliferation of head and neck squamous cell carcinomas.
Li H; Li X; Shi X; Li Z; Sun Y
Phytomedicine; 2019 Mar; 56():215-228. PubMed ID: 30668343
[TBL] [Abstract][Full Text] [Related]
13. Charge-Convertible Carbon Dots for Imaging-Guided Drug Delivery with Enhanced in Vivo Cancer Therapeutic Efficiency.
Feng T; Ai X; An G; Yang P; Zhao Y
ACS Nano; 2016 Apr; 10(4):4410-20. PubMed ID: 26997431
[TBL] [Abstract][Full Text] [Related]
14. Semi-synthetic product dihydroartemisinin inhibited fibronectin-1 and integrin-β1 and interfered with the migration of HCCLM6 cells via PI3K-AKT pathway.
Wu R; Gao Y; Wu J; Wang C; Yang L
Biotechnol Lett; 2020 Jun; 42(6):917-926. PubMed ID: 32072334
[TBL] [Abstract][Full Text] [Related]
15. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro.
Zhou HJ; Zhang JL; Li A; Wang Z; Lou XE
Cancer Chemother Pharmacol; 2010 May; 66(1):21-9. PubMed ID: 19756601
[TBL] [Abstract][Full Text] [Related]
16. TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib.
Hou C; Guo D; Yu X; Wang S; Liu T
Biomed Pharmacother; 2020 Jun; 126():109862. PubMed ID: 32120157
[TBL] [Abstract][Full Text] [Related]
17. Dihydroartemisinin: A Potential Natural Anticancer Drug.
Dai X; Zhang X; Chen W; Chen Y; Zhang Q; Mo S; Lu J
Int J Biol Sci; 2021; 17(2):603-622. PubMed ID: 33613116
[TBL] [Abstract][Full Text] [Related]
18. Dihydroartemisinin induces apoptosis and inhibits proliferation, migration, and invasion in epithelial ovarian cancer via inhibition of the hedgehog signaling pathway.
Liu Y; Gao S; Zhu J; Zheng Y; Zhang H; Sun H
Cancer Med; 2018 Nov; 7(11):5704-5715. PubMed ID: 30338663
[TBL] [Abstract][Full Text] [Related]
19. Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers.
Wang Z; Duan X; Lv Y; Zhao Y
Life Sci; 2019 Dec; 239():117013. PubMed ID: 31678287
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronic acid - dihydroartemisinin conjugate: Synthesis, characterization and in vitro evaluation in lung cancer cells.
Kumar R; Singh M; Meena J; Singhvi P; Thiyagarajan D; Saneja A; Panda AK
Int J Biol Macromol; 2019 Jul; 133():495-502. PubMed ID: 31004634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
